Association between zolpidem use and glaucoma risk: a Taiwanese population-based case-control study

Area of Science:

• Ophthalmology
• Pharmacology
• Epidemiology

Background:

• The association between zolpidem (sleeping pill) and glaucoma risk has not been previously studied in Taiwan.
• Understanding this relationship is crucial for patient safety and clinical practice.

Purpose of the Study:

• To investigate the potential link between zolpidem use and the subsequent development of glaucoma.
• To assess if zolpidem exposure increases glaucoma risk in a Taiwanese population.

Main Methods:

• A matched case-control study utilized data from Taiwan's National Health Insurance system.
• Cases were newly diagnosed glaucoma patients (2001-2010); controls were matched non-glaucoma subjects.
• Logistic regression models analyzed zolpidem exposure, dosage, and adjusted for medical comorbidities.

Main Results:

• Zolpidem use was significantly more prevalent in glaucoma patients (2.8%) compared to controls (2.0%).
• Zolpidem use was associated with a 1.19-fold increased risk of glaucoma (adjusted OR: 1.19, 95% CI: 1.02-1.38).
• High-dose zolpidem users (over 200 mg/year) showed a 1.31-fold increased risk (adjusted OR: 1.31, 95% CI: 1.03-1.68).

Conclusions:

• Findings suggest a potential association between zolpidem use and an elevated risk of developing glaucoma.
• Further research is recommended to confirm these findings and elucidate the underlying mechanisms.